Performance Evaluation

Updated November 2026

Performance evaluation is the process through which the manufacturer collects, appraises and analyses the data needed to support the safety and performance of an in vitro diagnostic medical device.

Regulation (EU) 2017/746 (IVDR) links this process to the device’s scientific validity, analytical performance and, where applicable, clinical performance.

This guide explains what performance evaluation means, which elements it comprises, which documents describe the process and its results, and how it relates to post-market surveillance and the SSP.

Document bearing the text Performance Evaluation Regulation EU 2017/746

In this guide

What is performance evaluation?

Performance evaluation is a systematic and continuous process involving the assessment and analysis of data needed to establish or verify the scientific validity, analytical performance and, where applicable, clinical performance of an in vitro diagnostic medical device.

Its main legal bases are Article 56 and Part A of Annex XIII to the IVDR.

The process supports the demonstration of conformity with the relevant general safety and performance requirements and must be consistent with the manufacturer’s stated intended purpose and risk management.

Clinical evidence is derived from the data and conclusions drawn from the assessment of these elements.

Performance evaluation is therefore not limited to checking the analytical performance of a test or preparing a final report.

Which devices require performance evaluation?

Performance evaluation applies to in vitro diagnostic medical devices subject to the relevant IVDR requirements, including class A devices.

It is not limited to class C and class D devices or to products whose conformity assessment requires the involvement of a notified body.

Its scope and depth depend on the device’s characteristics, risks, claimed performance and intended purpose.

The applicability of individual elements must be considered in relation to the product. Any omissions require the justification provided for in the Regulation.

A distinction applies to legacy devices, which continue to benefit from the transitional provisions of Article 110 of the IVDR, subject to the conditions set out in the Regulation.

MDCG 2022-8 distinguishes between requirements applicable during the transitional period and those needed for full IVDR compliance.

In particular, it clarifies that the application of post-market performance follow-up (PMPF) requirements does not automatically require manufacturers to draw up, retrospectively, a performance evaluation report in accordance with the IVDR.

Specific provisions also apply to devices manufactured and used only within health institutions, commonly referred to as in-house devices.

Article 5(5) of the IVDR establishes a specific exemption for these devices, subject to the conditions set out in the Regulation. The relevant general safety and performance requirements in Annex I remain applicable.

MDCG 2023-1 provides guidance on this exemption, which is distinct from the usual conformity assessment pathway for devices placed on the market.

Scientific validity, analytical performance and clinical performance

The IVDR distinguishes three related elements with different meanings.

Scientific validity concerns the association between an analyte or marker and a particular clinical condition or physiological state.

Analytical performance concerns the device’s ability to correctly detect or measure a particular analyte.

Clinical performance concerns the device’s ability to produce results correlated with a particular clinical condition or a physiological or pathological process or state, taking account of the target population and intended user.

These elements address different questions: the significance of what is being measured, how reliably it is measured, and how the results relate to the intended clinical context.

Their evaluation must be consistent with the device’s function, such as screening, diagnosis, aid to diagnosis or monitoring.

For in vitro diagnostic medical devices, clinical benefit is primarily linked to the provision of reliable medical information that supports diagnosis, screening, monitoring or other patient management decisions.

The benefit does not necessarily involve a direct therapeutic effect, as clinical outcomes may also depend on subsequent diagnostic or therapeutic decisions.

MDCG 2022-2 provides further guidance on the general principles of clinical evidence for in vitro diagnostic medical devices.

How does the process work?

Performance evaluation starts with the device’s intended purpose and characteristics.

Relevant aspects include the analyte or marker, specimen type, target population, intended users and claimed performance.

The process involves identifying available data, assessing their quality and relevance, identifying gaps and generating any additional data needed.

Sources may include scientific literature, performance studies, published experience and information collected after the device has been placed on the market.

The evaluation must consider both favourable and unfavourable data and interpret the results in the light of the state of the art.

Its conclusions must support the manufacturer’s claims and remain consistent with risk management and the information supplied to users.

Performance evaluation therefore contributes to demonstrating conformity with the applicable general safety and performance requirements through evidence consistent with the device’s intended purpose and technical documentation.

Performance evaluation plan and report

Two documents play a central role:

  • the Performance Evaluation Plan (PEP);
  • the Performance Evaluation Report (PER).

The plan sets out the approach to the process, the elements to be evaluated and the criteria used to collect and generate the necessary evidence.

The report presents the data considered, their assessment and the conclusions drawn about the clinical evidence for the device.

PER includes the scientific validity report, the analytical performance report and the clinical performance report, together with an assessment of these reports, as applicable.

Article 56(5) requires the PER to form part of the device’s technical documentation referred to in Annex II.

The report must make it possible to understand the basis for the manufacturer’s conclusions.

The plan and the report are not interchangeable: the plan establishes the approach to the evaluation, while the report documents its results.

Performance evaluation and performance studies

Performance evaluation and performance studies are not interchangeable terms.

The overall process through which the available data are assessed and brought together is performance evaluation.

A performance study is a study undertaken to establish or confirm a device’s analytical or clinical performance.

Study results therefore constitute one of the sources used in the evaluation.

Article 56(4) requires clinical performance studies to be carried out unless reliance on other sources of clinical performance data is duly justified.

This does not mean that every device requires the same type of study. The study design and applicable requirements depend on the characteristics of the study and the device.

The provisions governing performance studies are set out in Chapter VI and Annexes XIII and XIV to the IVDR.

MDCG 2025-5 provides further clarification on the different types of performance studies and the applicable provisions.

Roles of the manufacturer and the notified body

The manufacturer is responsible for planning, conducting, documenting and updating the performance evaluation.

Where required by the applicable conformity assessment procedure, the notified body examines the documentation and the evidence supporting the device’s safety and performance.

The scope and arrangements for this assessment depend on the device class and the applicable procedure.

The absence of a notified body from the conformity assessment of a particular device does not remove the manufacturer’s obligations relating to performance evaluation.

Similarly, the involvement of a notified body does not transfer responsibility for the evidence and conclusions in the technical documentation from the manufacturer to the notified body.

Updates, PMS and PMPF

Performance evaluation is a continuous process.

Article 56(6) requires the performance evaluation and its documentation to be updated throughout the device’s life cycle.

Updates also draw on information obtained through post-market surveillance, or PMS, and post-market performance follow-up, or PMPF.

Post-market surveillance involves collecting and analysing information on experience gained with the device after it has been placed on the market.

PMPF helps confirm the device’s safety and performance over time and identify previously unrecognised risks or limitations.

Part B of Annex XIII also requires a justification to be provided and documented in the performance evaluation report where PMPF is not deemed appropriate for a specific device.

The information collected may confirm existing conclusions or indicate a need for further investigation and changes to the documentation.

For class C and class D devices, Article 56(6) requires the performance evaluation report to be updated when necessary, but at least annually.

The principle of updating the evaluation throughout the device’s life cycle also applies to other classes. The absence of this specific annual frequency does not make performance evaluation a one-off activity.

Relationship with the SSP

For devices covered by Article 29 of the IVDR, the Summary of Safety and Performance, or SSP, provides public access to selected information derived from the performance evaluation.

SSP includes a summary of the performance evaluation and relevant information on PMPF.

The performance evaluation report and the SSP serve different purposes and audiences. The PER forms part of the technical documentation, while the SSP presents the information required by the Regulation to the public.

SSP does not replace the PER and must remain consistent with the updated evidence.

Article 56(6) requires the SSP to be updated as soon as possible, where necessary.

Further reading: Summary of Safety and Performance | SSP.

Why this guide is not a performance evaluation template

This page explains the purpose and general regulatory framework of performance evaluation.

It does not provide a completed PEP or PER template or determine which data or studies are sufficient for a particular device.

The content, methods and conclusions depend on the product’s intended purpose, characteristics, risks and available evidence.

This guide is for information only and does not establish performance evaluation procedures for individual products.


Informational note

This guide is published for informational purposes only and does not constitute regulatory, legal, technical or professional advice.

The information is based on publicly available sources and was checked as of the publication or last update date of this page. It may therefore not reflect subsequent changes or developments.

For assessments relating to specific cases, it is necessary to refer to the official texts, the updated documentation of the competent authorities and, where appropriate, qualified professionals.


Official sources


Share this guide

If you find this guide useful, you can share it with other professionals interested in IVDR.


Want to stay updated on MDR and IVDR?

Subscribe to MDN – Medical Device News for free.

Subscribers receive the newsletter by email every Monday, one week before publication on the website.

One email per week. No spam. Privacy Policy.


Related resources


Copyright and reuse

© Simone Ronco. Unless otherwise stated, the editorial content of this guide is an original work.

Short excerpts may be quoted with attribution to the author and a link to the original page.

Full reproduction, translation, adaptation or commercial use of the content requires prior written permission.